Dr Lalchandani Labs (BSE: DLCL) had a P/E of 94.4× on 6 Nov 2026, above the industry P/E of 52.8×, and the shares are 72% below their 52-week high. Sales fell 6.0% a year over 3 years; its ROCE of 0.8% is the lowest among the 7 largest Diagnostics & Research peers, though net profit is above operating profit, which points to a one-off gain. Debt is 0.15× equity. It is listed on an SME platform with a market cap of ₹5.71 Cr, ranked 17th of 18 Diagnostics & Research companies by market cap; the shares fell 72% over the past year.
- ₹6.70
- ₹6.70
- ₹6.25
- ₹6.70
- 32K
Health check
- ReturnsBehind
−71.6% over a year, better than 0 of 7 peers.
- Price tagDistorted
A one-off gain inflates profit, so P/E isn’t comparable right now.
- GrowthShrinking
Sales −6.0% a year over 3 years.
- ProfitabilityWeak
ROCE 0.8% vs peer median 19.1%.
- Balance sheetStretched
Debt 0.15× equity, interest covered 6.6×, Piotroski 3 of 9.
- Red flags5 to check
Return on equity is low at 0.5%.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹5.71 Cr
- Small cap
- P/E
- 94.4
- Industry 52.8
- Price to book
- 0.65
- Peers 11.99
- Dividend yield
- 0.00%
- ROE
- 0.5%
- Peers 17.7%
- ROCE
- 0.8%
- Peers 19.1%
- Debt to equity
- 0.15
- Debt ₹2.06 Cr
- EPS (TTM)
- ₹0.07
- OPM (TTM)
- −22.2%
- Net margin 1.5%
- Sales growth
- −8.3%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 1.36
- EV/EBITDA 98.9
Strengths and risks
Risks to check
- Return on equity is low at 0.5%.
- Quarterly sales down 8.3% on a year ago.
- Net profit is above operating profit, so a one-off gain is likely flattering earnings.
- P/E of 94.4 against an industry P/E of 52.8.
- 72% below its 52-week high.
About Dr Lalchandani Labs
Dr Lalchandani Labs Limited provides diagnostic and related healthcare tests and services in India. The company offers doctor consultation, pathology, radiology, hospital lab management, corporate health checkup, and blood bank services, as well as X-ray, TMT, ultrasound, 2D-echo, and medical fitness examinations. It also offers its products online. The company serves individual patients, hospitals and other healthcare providers, and corporate customers.…
- Headquarters
- New Delhi
- Sector
- Healthcare
- ISIN
- INE871Z01013
- Website
- lalchandanipathlab.com
Price range
- Avg volume (3M)
- 27.2K
- 1-year return
- minus 71.6%
- From 52-week high
- minus 72.1%
Peers · Diagnostics & Research
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SAILIFESai Life Sciences | 1,785.10 | plus 11.95% | 37,929 | 101.5 | 15.22 | 18.1% | 15.1% | 28.7% | 21.3% | 226.8% | 0.00% | plus 72.7% |
| LALPATHLABDr. Lal Path Labs | 1,970.00 | plus 0.16% | 32,941 | 56.5 | 11.99 | 25.7% | 22.6% | 30.2% | 11.1% | 28.3% | 1.02% | plus 24.7% |
| SYNGENESyngene International | 417.30 | plus 0.77% | 16,772 | 90.3 | 3.46 | 8.3% | 3.9% | 25.7% | 5.4% | −12.0% | 0.30% | minus 36.0% |
| VIJAYAVijaya Diagnostic Centre | 1,468.60 | plus 2.15% | 15,126 | 74.4 | 14.29 | 19.1% | 21.2% | 43.1% | 21.0% | 26.9% | 0.14% | plus 40.2% |
| METROPOLISMetropolis Healthcare | 568.75 | minus 0.39% | 11,803 | 52.8 | 7.17 | 15.7% | 14.6% | 21.7% | 12.7% | 10.0% | 0.35% | plus 12.5% |
| THYROCAREThyrocare Technologies | 493.10 | plus 0.68% | 7,848 | 55.0 | 14.75 | 33.8% | 26.4% | 32.2% | 16.7% | 36.2% | 1.89% | plus 8.3% |
| VIMTALABSVimta Labs | 496.45 | minus 2.14% | 2,219 | 27.9 | 4.52 | 21.0% | 17.7% | 34.7% | 8.9% | 17.2% | 0.40% | minus 23.3% |
| DLCLDr Lalchandani Labs | 6.61 | minus 1.34% | 6 | 94.4 | 0.65 | 0.8% | 0.5% | −22.2% | −6.0% | – | 0.00% | minus 71.6% |
| Median of 7 peers | – | 0.68% | 15,126 | 56.5 | 11.99 | 19.1% | 17.7% | 30.2% | 12.7% | 26.9% | 0.35% | 12.5% |
Quarterly results
This company doesn’t report these figures in a format we can read yet.
Profit & loss
- Sales CAGR 3Y
- −6.0%
- ROE
- 0.5%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 5 | 4.8 | 4.5 | 4.2 | |
| – | minus 4.6% | minus 7.4% | minus 6.0% | |
| 4.8 | 4.2 | 3.5 | 4.1 | |
| 0.2 | 0.6 | 0.9 | 0.1 | |
| 4.4% | 11.8% | 20.7% | 1.7% | |
| −0.1 | −0 | 0 | 0 | |
| 0.9 | 0.4 | 0.1 | 0 | |
| 0.7 | 0.6 | 0.6 | 0.6 | |
| −0.1 | 1 | 0.1 | 0.6 | |
| −1.6 | 0.6 | 0.4 | 0.1 | |
| – | – | −3.7% | 35.0% | |
| −1.6 | 0.6 | 0.4 | 0.1 | |
| – | – | minus 32.4% | minus 84.8% | |
| -2.63 | 1.04 | 0.96 | – |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 4.3 | 4.3 | 4.3 | 8.6 | |
| 4.6 | 5.2 | 5.6 | 5.5 | |
| 6.4 | 3.5 | 4.1 | 2.1 | |
| 2.4 | 2 | 1.7 | 1.4 | |
| 17.7 | 15 | 15.7 | 17.6 | |
| 5 | 3.7 | 3.3 | 3.1 | |
| – | 0.2 | 0 | – | |
| 3.1 | 2.3 | 3.3 | 4.1 | |
| 9.6 | 8.8 | 9.2 | 10.4 | |
| 17.7 | 15 | 15.7 | 17.6 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 0 | −0.2 | 0.4 | −0.8 | |
| −0.2 | 1 | 0.1 | −0.5 | |
| −0.2 | −1.6 | 0.5 | 2.1 | |
| −0.4 | −0.8 | 1 | 0.8 | |
| −0.3 | −0.1 | −0.2 | −0.3 | |
| −0.3 | −0.3 | 0.3 | −1.1 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.